Tag Archives: Lilly

Lilly to Acquire Versanis Bio; Brenzavvy Available by Prescription at Mark Cuban Cost Plus Drug Company; Abbott Initiates Libre 3 trial in T2DM and Basal Therapy; Nemaura FY ‘22 Earnings Update

Four cardiometabolic-related news items have been observed: Lilly and Versanis Bio announced a definitive agreement for Lilly to acquire Versanis (view press release); TheracosBio announced Brenzavvy (bexagliflozin) is available by prescription through the Mark Cuban Cost Plus Drug Company (view press release); Abbott initiated a new trial evaluating its FreeStyle Libre 3 in adults with T2DM on basal therapy (view CT.gov record); and Nemaura Medical announced business updates and financial results for its FY ‘22 (view press release). Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Lilly Initiates Three New Ph3 Retatrutide Obesity Trials; Zealand Ph1 Amylin Analog Results; Zealand Dasiglucagon CHI NDA Submitted; Sanofi Signs M1Pram Exclusivity Agreement with Adocia; Dexcom G7 Approved in Canada

Five cardiometabolic-related news items have been observed: Lilly initiated three new trials in the Ph3 retatrutide obesity program, TRIUMPH (TRIUMPH-1; TRIUMPH-2; TRIUMPH-4); Zealand announced positive results from Part 1 of the Ph1 MAD trial evaluating its amylin analog, ZP8396 (view press release); Zealand also submitted the dasiglucagon NDA for congenital hyperinsulinism (view press release); Adocia signed an exclusivity agreement with Sanofi for M1Pram (view press release); and Dexcom’s G7 CGM received Health Canada approval for individuals aged 2 years and older (view press release). Below, FENIX provides highlights and insights into the respective news items, including a projected regulatory timeline for retatrutide and brief thoughts on next-gen obesity drugs.

This content is for Read Less members only.
Already a member? Log in here

Lilly to Acquire Sigilon Therapeutics; FDA Approves First Beta Cell Replacement Therapy for T1DM

Two cardiometabolic-related news items have been observed: Lilly announced it entered into an agreement to acquire Sigilon Therapeutics for ~$309.6M (view press release); and FDA approved Lantidra as the first beta cell replacement therapy for the treatment of T1DM in adults with severe hypoglycemia (view press release). Below, FENIX provides highlights and insights into the respective news items, including brief thoughts on the future of T1DM cell therapies.

This content is for Read Less members only.
Already a member? Log in here

FENIX Analysis: Breaking Through Novo and Lilly’s Obesity Duopoly

With all of the (justified) hype surrounding the obesity market and the promising pipelines from a multitude of companies, a question has arisen regarding the potential of a new mega-partnership to compete with Novo Nordisk and Lilly. Below, FENIX provides thoughts and rationale on why CVRM history could repeat itself with a partnership between AstraZeneca and either Boehringer Ingelheim, Amgen, or Pfizer could be on the horizon. FENIX will also soon author a follow-up to this obesity partnership blast with a subsequent analysis discussing the rationale for why a Zealand acquisition could be an alternative option.

This content is for Read Less members only.
Already a member? Log in here

ADA 2023 Key Press Releases (June 24)

On the second day of ADA 2023, ten cardiometabolic-related news items were observed from Lilly, Zealand, BI, Novo Nordisk, Biomea Fusion, Sciwind Biosciences, Medtronic, Vertex, and Esperion. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Already a member? Log in here

June CHMP Agenda; AstraZeneca Discontinues Oral GLP-1RA Development; Lilly Launches Insulin Affordability Awareness Campaign

Three cardiometabolic-related news have been observed: the CHMP agenda (view here) for this month’s meeting (June 19-22) has been released, including Jardiance’s EMPA-KIDNEY and Mounjaro obesity indication extensions; AstraZeneca announced it is discontinuing development of its oral, AZD0186 (view article); and Lilly announced a partnership with ADA and Adam Duvall to increase awareness of Lilly’s insulin affordability programs (view press release). Below, FENIX provides context and insight on the respective news items, including insight into how Novo’s OASIS 1 readout likely influenced AZ’s decision.

This content is for Read Less members only.
Already a member? Log in here

Lilly Partners with Verve Therapeutics for Lp(a) Gene Editing Program; Zucara Receives Funding from JDRF

Two cardiometabolic-related news items have been observed: Verve Therapeutics announced a partnership with Lilly to advance Verve’s gene editing program targeting Lp(a) for the treatment of ASCVD, ischemic stroke, thrombosis, and aortic stenosis (view press release); and Zucara Therapeutics announced it received $2M in funding from JDRF for its ZONE study, a Ph2 trial evaluating ZT-01 to reduce nocturnal hypoglycemia events in T1DM patients (view press release). Below, FENIX provides context and insight on the respective news items, including brief thoughts on the Verve partnership.

This content is for Read Less members only.
Already a member? Log in here

AstraZeneca Partners for T1DM Cell Therapy; New Lilly Care Trial

Two cardiometabolic-related news items have been observed: AstraZeneca and Quell Therapeutics announced a collaboration to develop, manufacture, and commercialize autologous, engineered Treg cell therapies for T1DM and IBD; and Lilly initiated a trial evaluating adherence and glucose control of its connected Tempo pen system in conjunction with Dexcom and Glooko (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items, including thoughts on how AZ’s collaboration fits with another one of its recent partnerships.

This content is for Read Less members only.
Already a member? Log in here

Lilly Initiates Ph3 Retatrutide Obesity Program; UnitedHealthcare Expands Coverage to Eversense E3 CGM

Two cardiometabolic-related news items have been observed: Lilly initiated the first trial in the Ph3 retatrutide obesity program (TRIUMPH-3; view CT.gov record); and Senseonics announced UnitedHealthcare will cover the Eversense E3 CGM starting July 1, 2023, for T1DM and insulin-requiring T2DM patients. Below, FENIX provides highlights of the respective news items, including insight into the potential retatrutide Ph3 TRIUMPH program and Lilly’s strategy for an obesity CVOT.  

This content is for Read Less members only.
Already a member? Log in here